Igor Alexandre Protzner Morbeck
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Igor Alexandre Protzner Morbeck has a total of 135 co-authors. Here are the top co-authors by number of shared publications:
- Daniel Herchenhorn
Latin American Cooperative Oncology Group—LACOG, Porto Alegre, Brazil
6 shared publications - Andrey Soares
Hospital Israelita Albert Einstein, São Paulo, Brazil
5 shared publications - Fernando Sabino Marques Monteiro
Latin American Cooperative Oncology Group - LACOG, Porto Alegre, Brazil
5 shared publications - Diogo Assed Bastos
Latin American Cooperative Oncology Group (LACOG), Porto Alegre, Brazil
4 shared publications - Fernando Cotait Maluf
Latin American Cooperative Oncology Group (LACOG), Porto Alegre, Brazil
4 shared publications - Vinicius Carrera Souza
Oncologia D’OR , Salvador
4 shared publications
Latest Publications
- Open Access
- 1 May 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 12 (5) , e2500712
Prostate Cancer Treatment Patterns and Inequities Among Racial Groups in Brazil's Public Health System: Insights From a 16-Year Real-World Study
PURPOSE: The Brazilian Public Health System (BPHS) provides sole health coverage for approximately 77% of the population. Analyzing BPHS data enables nationwide assessment of epidemiology, treatment patterns, and costs for men with prostate cancer (PCa). METHODS: We conducted a retrospective, population-based cohort study using linked administrative data from the BPHS Database DATASUS for patients with PCa treated in the BPHS from January 1, 2008, to March 31, 2023. Variables include demographics, clinical features, stage, treatments, and health care utilization. The primary objective was to evaluate the impact of race on stage at diagnosis, treatment delivery, and treatment costs. RESULTS: A total of 670,205 patients with PCa were treated during the study period; 277,030 (41.4%) were White and 393,175 (58.6%) non-White. Mean age at diagnosis was 72.9 years (40-99). Approximately 56% were diagnosed with stage I-III disease (56.1% v 55.5%), and 21% with metastatic disease (19.7% v 21.2%), with non-White men more frequently presenting with advanced stage ( P < .001). White men more commonly received local therapy in stage I, whereas non-White men received local therapy more frequently in stage III ( P < .001). Among 125,759 men with stage IV disease who received systemic therapy, only 22,393 (17.8%) received docetaxel, while use of first-generation antiandrogens and estrogens remained high (25%). Total PCa-directed expenditures reached In$ 1.83 billion, with mean costs 16.2% higher for White patients than for non-White patients. CONCLUSION: In the BPHS, race was associated with more advanced stages at diagnosis and differences in treatment delivery. High rates of de novo metastatic disease, underuse of docetaxel, and persistent use of agents without survival benefit highlight urgent gaps in PCa care. These findings may guide PCa policy in Brazil and other low- and middle-income countries.
- 1 May 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 12 (5) , e2500712
Open AccessProstate Cancer Treatment Patterns and Inequities Among Racial Groups in Brazil's Public Health System: Insights From a 16-Year Real-World Study
PURPOSE: The Brazilian Public Health System (BPHS) provides sole health coverage for approximately 77% of the population. Analyzing BPHS data enables nationwide assessment of epidemiology, treatment patterns, and costs for men with prostate cancer (PCa). METHODS: We conducted a retrospective, population-based cohort study using linked administrative data from the BPHS Database DATASUS for patients with PCa treated in the BPHS from January 1, 2008, to March 31, 2023. Variables include demographics, clinical features, stage, treatments, and health care utilization. The primary objective was to evaluate the impact of race on stage at diagnosis, treatment delivery, and treatment costs. RESULTS: A total of 670,205 patients with PCa were treated during the study period; 277,030 (41.4%) were White and 393,175 (58.6%) non-White. Mean age at diagnosis was 72.9 years (40-99). Approximately 56% were diagnosed with stage I-III disease (56.1% v 55.5%), and 21% with metastatic disease (19.7% v 21.2%), with non-White men more frequently presenting with advanced stage ( P < .001). White men more commonly received local therapy in stage I, whereas non-White men received local therapy more frequently in stage III ( P < .001). Among 125,759 men with stage IV disease who received systemic therapy, only 22,393 (17.8%) received docetaxel, while use of first-generation antiandrogens and estrogens remained high (25%). Total PCa-directed expenditures reached In$ 1.83 billion, with mean costs 16.2% higher for White patients than for non-White patients. CONCLUSION: In the BPHS, race was associated with more advanced stages at diagnosis and differences in treatment delivery. High rates of de novo metastatic disease, underuse of docetaxel, and persistent use of agents without survival benefit highlight urgent gaps in PCa care. These findings may guide PCa policy in Brazil and other low- and middle-income countries.
- Open Access
- 9 April 2024
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 150 (4) , 1-17
Advanced renal cell carcinoma management: the Latin American Cooperative Oncology Group (LACOG) and the Latin American Renal Cancer Group (LARCG) consensus update
Purpose: Renal cell carcinoma is an aggressive disease with a high mortality rate. Management has drastically changed with the new era of immunotherapy, and novel strategies are being developed; however, identifying systemic treatments is still challenging. This paper presents an update of the expert panel consensus from the Latin American Cooperative Oncology Group and the Latin American Renal Cancer Group on advanced renal cell carcinoma management in Brazil. Methods: A panel of 34 oncologists and experts in renal cell carcinoma discussed and voted on the best options for managing advanced disease in Brazil, including systemic treatment of early and metastatic renal cell carcinoma as well as nonclear cell tumours. The results were compared with the literature and graded according to the level of evidence. Results: Adjuvant treatments benefit patients with a high risk of recurrence after surgery, and the agents used are pembrolizumab and sunitinib, with a preference for pembrolizumab. Neoadjuvant treatment is exceptional, even in initially unresectable cases. First-line treatment is mainly based on tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs); the choice of treatment is based on the International Metastatic Database Consortium (IMCD) risk score. Patients at favourable risk receive ICIs in combination with TKIs. Patients classified as intermediate or poor risk receive ICIs, without preference for ICI + ICIs or ICI + TKIs. Data on nonclear cell renal cancer treatment are limited. Active surveillance has a place in treating favourable-risk patients. Either denosumab or zoledronic acid can be used for treating metastatic bone disease. Conclusion: Immunotherapy and targeted therapy are the standards of care for advanced disease. The utilization and sequencing of these therapeutic agents hinge upon individual risk scores and responses to previous treatments. This consensus reflects a commitment to informed decision-making, drawn from professional expertise and evidence in the medical literature.
- 9 April 2024
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 150 (4) , 1-17
Open AccessAdvanced renal cell carcinoma management: the Latin American Cooperative Oncology Group (LACOG) and the Latin American Renal Cancer Group (LARCG) consensus update
Purpose: Renal cell carcinoma is an aggressive disease with a high mortality rate. Management has drastically changed with the new era of immunotherapy, and novel strategies are being developed; however, identifying systemic treatments is still challenging. This paper presents an update of the expert panel consensus from the Latin American Cooperative Oncology Group and the Latin American Renal Cancer Group on advanced renal cell carcinoma management in Brazil. Methods: A panel of 34 oncologists and experts in renal cell carcinoma discussed and voted on the best options for managing advanced disease in Brazil, including systemic treatment of early and metastatic renal cell carcinoma as well as nonclear cell tumours. The results were compared with the literature and graded according to the level of evidence. Results: Adjuvant treatments benefit patients with a high risk of recurrence after surgery, and the agents used are pembrolizumab and sunitinib, with a preference for pembrolizumab. Neoadjuvant treatment is exceptional, even in initially unresectable cases. First-line treatment is mainly based on tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs); the choice of treatment is based on the International Metastatic Database Consortium (IMCD) risk score. Patients at favourable risk receive ICIs in combination with TKIs. Patients classified as intermediate or poor risk receive ICIs, without preference for ICI + ICIs or ICI + TKIs. Data on nonclear cell renal cancer treatment are limited. Active surveillance has a place in treating favourable-risk patients. Either denosumab or zoledronic acid can be used for treating metastatic bone disease. Conclusion: Immunotherapy and targeted therapy are the standards of care for advanced disease. The utilization and sequencing of these therapeutic agents hinge upon individual risk scores and responses to previous treatments. This consensus reflects a commitment to informed decision-making, drawn from professional expertise and evidence in the medical literature.
- 1 June 2023
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 41 (16_suppl) , e17106
Impact of COVID-19 pandemic on the treatment of prostate cancer in the Brazilian public health system.
- 1 June 2023
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 41 (16_suppl) , e17106
Impact of COVID-19 pandemic on the treatment of prostate cancer in the Brazilian public health system.
- 1 June 2023
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 41 (16_suppl) , 5025
Prostate cancer public health system database from Brazil: Racial disparities and heterogeneity of treatment interventions to understand evidence-based practice patterns in a large real-world database.
- 1 June 2023
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 41 (16_suppl) , 5025
Prostate cancer public health system database from Brazil: Racial disparities and heterogeneity of treatment interventions to understand evidence-based practice patterns in a large real-world database.
- Open Access
- 10 September 2022
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 21 (2) , e58-e69
“Non-metastatic, Castration-resistant Prostate Cancer: Diagnostic and Treatment Recommendations by an Expert Panel from Brazil”
- 10 September 2022
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 21 (2) , e58-e69
Open Access“Non-metastatic, Castration-resistant Prostate Cancer: Diagnostic and Treatment Recommendations by an Expert Panel from Brazil”
- Open Access
- 1 December 2021
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 7 (7) , 538-544
Consensus on Treatment and Follow-Up for Biochemical Recurrence in Castration-Sensitive Prostate Cancer: A Report From the First Global Prostate Cancer Consensus Conference for Developing Countries
To present a summary of the treatment and follow-up recommendations for the biochemical recurrence in castration-sensitive prostate cancer (PCa) acquired through a questionnaire administered to 99 PCa experts from developing countries during the Prostate Cancer Consensus Conference for Developing Countries. A total of 27 questions were identified as related to this topic from more than 300 questions. The clinician's responses were tallied and presented in a percentage format. Topics included the use of imaging for staging biochemical recurrence, treatment recommendations for three different clinical scenarios, the field of radiation recommended, and follow-up. Each question had 5-7 relevant response options, including “abstain” and/or “unqualified to answer,” and investigated not only recommendations but also if a limitation in resources would change the recommendation. For most questions, a clear majority (> 50%) of clinicians agreed on a recommended treatment for imaging, treatment scenarios, and follow-up, although only a few topics reached a consensus > 75%. Limited resources did affect several areas of treatment, although in many cases, they reinforced more stringent criteria for treatment such as prostate-specific antigen values > 0.2 ng/mL and STAMPEDE inclusion criteria as a basis for recommending treatment. A majority of clinicians working in developing countries with limited resources use similar cutoff points and selection criteria to manage patients treated for biochemically recurrent castration-sensitive PCa.
- 1 December 2021
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 7 (7) , 538-544
Open AccessConsensus on Treatment and Follow-Up for Biochemical Recurrence in Castration-Sensitive Prostate Cancer: A Report From the First Global Prostate Cancer Consensus Conference for Developing Countries
To present a summary of the treatment and follow-up recommendations for the biochemical recurrence in castration-sensitive prostate cancer (PCa) acquired through a questionnaire administered to 99 PCa experts from developing countries during the Prostate Cancer Consensus Conference for Developing Countries. A total of 27 questions were identified as related to this topic from more than 300 questions. The clinician's responses were tallied and presented in a percentage format. Topics included the use of imaging for staging biochemical recurrence, treatment recommendations for three different clinical scenarios, the field of radiation recommended, and follow-up. Each question had 5-7 relevant response options, including “abstain” and/or “unqualified to answer,” and investigated not only recommendations but also if a limitation in resources would change the recommendation. For most questions, a clear majority (> 50%) of clinicians agreed on a recommended treatment for imaging, treatment scenarios, and follow-up, although only a few topics reached a consensus > 75%. Limited resources did affect several areas of treatment, although in many cases, they reinforced more stringent criteria for treatment such as prostate-specific antigen values > 0.2 ng/mL and STAMPEDE inclusion criteria as a basis for recommending treatment. A majority of clinicians working in developing countries with limited resources use similar cutoff points and selection criteria to manage patients treated for biochemically recurrent castration-sensitive PCa.
- Open Access
- 1 December 2021
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 7 (7) , 559-571
Consensus on the Treatment and Follow-Up for Metastatic Castration-Resistant Prostate Cancer: A Report From the First Global Prostate Cancer Consensus Conference for Developing Countries (PCCCDC)
PURPOSE: To present a summary of the recommendations for the treatment and follow-up for metastatic castration-resistant prostate cancer (mCRPC) as acquired through a questionnaire administered to 99 physicians working in the field of prostate cancer in developing countries who attended the Prostate Cancer Consensus Conference for Developing Countries. METHODS: A total of 106 questions out of more than 300 questions addressed the use of imaging in staging mCRPC, treatment recommendations across availability and response to prior drug treatments, appropriate drug treatments, and follow-up, and those same scenarios when limited resources needed to be considered. Responses were compiled and the percentages were presented by clinicians to support each response. Most questions had five to seven relevant options for response including abstain and/or unqualified to answer, or in the case of yes or no questions, the option to abstain was offered. RESULTS: Most of the recommendations from this panel were in line with prior consensus, including the preference of a new antiandrogen for first-line therapy of mCRPC. Important aspects highlighted in the scenario of limited resources included the option of docetaxel as treatment preference as first-line treatment in several scenarios, docetaxel retreatment, consideration for reduced doses of abiraterone, and alternative schedules of an osteoclast-targeted therapy. CONCLUSION: There was wide-ranging consensus in the treatment for men with mCRPC in both optimal and limited resource settings.
- 1 December 2021
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 7 (7) , 559-571
Open AccessConsensus on the Treatment and Follow-Up for Metastatic Castration-Resistant Prostate Cancer: A Report From the First Global Prostate Cancer Consensus Conference for Developing Countries (PCCCDC)
PURPOSE: To present a summary of the recommendations for the treatment and follow-up for metastatic castration-resistant prostate cancer (mCRPC) as acquired through a questionnaire administered to 99 physicians working in the field of prostate cancer in developing countries who attended the Prostate Cancer Consensus Conference for Developing Countries. METHODS: A total of 106 questions out of more than 300 questions addressed the use of imaging in staging mCRPC, treatment recommendations across availability and response to prior drug treatments, appropriate drug treatments, and follow-up, and those same scenarios when limited resources needed to be considered. Responses were compiled and the percentages were presented by clinicians to support each response. Most questions had five to seven relevant options for response including abstain and/or unqualified to answer, or in the case of yes or no questions, the option to abstain was offered. RESULTS: Most of the recommendations from this panel were in line with prior consensus, including the preference of a new antiandrogen for first-line therapy of mCRPC. Important aspects highlighted in the scenario of limited resources included the option of docetaxel as treatment preference as first-line treatment in several scenarios, docetaxel retreatment, consideration for reduced doses of abiraterone, and alternative schedules of an osteoclast-targeted therapy. CONCLUSION: There was wide-ranging consensus in the treatment for men with mCRPC in both optimal and limited resource settings.
- Open Access
- 1 July 2021
- Published by Publicacoes Cientificas de Acesso Aberto e Editora LTDA in Brazilian Journal of Case Reports
- Vol. 1 (3) , 86-89
Flagellate Erythema Secondary to Bleomycin for Non-Seminomatous Testis Tumor
The development of flagellate erythema secondary to bleomycin treatment is a rare adverse effect. The prevalence varies between 8 to 22% of patients and it is becoming rarer. Flagellate erythema presents as a scaly erythematous papule. A lower amount of bleomycin hydrolase in regions with reduced production, such as skin and lungs, decreases bleomycin degradation, which allows its accumulation in tissues, triggering an inflammatory process, especially in patients with lower basal enzyme function. We report a clinical case of a severe presentation of flagellate erythema secondary to a patient ongoing bleomycin, etoposide and platinum (BEP) based chemotherapy of non-seminomatous testis cancer.
- 1 July 2021
- Published by Publicacoes Cientificas de Acesso Aberto e Editora LTDA in Brazilian Journal of Case Reports
- Vol. 1 (3) , 86-89
Open AccessFlagellate Erythema Secondary to Bleomycin for Non-Seminomatous Testis Tumor
The development of flagellate erythema secondary to bleomycin treatment is a rare adverse effect. The prevalence varies between 8 to 22% of patients and it is becoming rarer. Flagellate erythema presents as a scaly erythematous papule. A lower amount of bleomycin hydrolase in regions with reduced production, such as skin and lungs, decreases bleomycin degradation, which allows its accumulation in tissues, triggering an inflammatory process, especially in patients with lower basal enzyme function. We report a clinical case of a severe presentation of flagellate erythema secondary to a patient ongoing bleomycin, etoposide and platinum (BEP) based chemotherapy of non-seminomatous testis cancer.